Suchergebnisse - "Robak, Tadeusz"

PubPharm (51)

1

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW) : 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Niemann, C. | Munir, T. | Moreno, C. | +21

2

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia : results from the randomized, phase 3 BRIGHT AML 1019 trial

enthalten in: Leukemia | 2023

von Sekeres, M. | Montesinos, P. | Novak, J. | +17

CommentIn: Leukemia. 2023 Dec;37(12):2520-2521. - PMID 37816956

3

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia : a global phase 3 randomized study

enthalten in: Blood advances | 2023

von Fenaux, P. | Gobbi, M. | Kropf, P. | +23

4

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS) : interim analysis of a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Dytfeld, D. | Wróbel, T. | Jamroziak, K. | +30

CommentIn: Lancet Oncol. 2023 Feb;24(2):118-119. - PMID 36642082

5

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma : Interim Analysis of a Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Hillmen, P. | Eichhorst, B. | Brown, J. | +25

6

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

enthalten in: The New England journal of medicine | 2023

von Brown, J. | Eichhorst, B. | Hillmen, P. | +25

CommentIn: Nat Rev Clin Oncol. 2023 Feb;20(2):64. - PMID 36543933

7

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA) : a randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Tam, C. | Brown, J. | Kahl, B. | +28

CommentIn: Lancet Oncol. 2022 Aug;23(8):965-967. - PMID 35810752

8

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia : results from the phase 3b VENICE II trial

enthalten in: Leukemia & lymphoma | 2022

von Cochrane, T. | Enrico, A. | Gomez-Almaguer, D. | +12

9

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia : Results of the First Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Byrd, J. | Hillmen, P. | Ghia, P. | +21

CommentIn: J Clin Oncol. 2021 Nov 1;39(31):3419-3422. - PMID 34310198

10

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

enthalten in: The New England journal of medicine | 2020

von Wei, A. | Döhner, H. | Pocock, C. | +127

CommentIn: Nat Rev Clin Oncol. 2021 Mar;18(3):132. - PMID 33462426

1
2
3
4
5
6
Nächster »
[6]